The science of more life together
Aevum Pet applies genomic processing knowledge to dogs and cats, building around one permanent genome and a health picture that can grow over time.
We know how to process and structure genomic information. What we do not yet claim is a large history of dog and cat samples, completed assay validation or a finished partner network.
That distinction matters. Aevum Pet begins with the strongest operational foundation in the blueprint — outsourced target 30× whole-genome sequencing, a raw-data archive and evidence-graded interpretation.
The broader ambition is longitudinal: bring carefully selected repeatable signals into the same record, so owners and vets can see not only what a pet inherited but how its picture changes.
Our principle is simple: be ambitious about the product and conservative about every claim.
Honest before impressive
Readiness, uncertainty and limitations remain visible.
Whole genome before novelty
A permanent full-data foundation, not a shallow entertainment test.
Longitudinal before one-off
The value should grow as evidence and measurements accumulate.
Veterinary before autonomous
The report supports professional judgement and stops before treatment.
Knowledge first. Claims only when earned.
The product is being shaped around genomic operations experience, external laboratory capacity and transparent evidence standards.
Based in Switzerland
Operated from a country with a long tradition in precision medicine, laboratory standards and data protection.
Genomic processing knowledge
Experience handling and interpreting complex genomic information.
Partner-led operations
Sequencing, assays and devices evaluated through specialist providers rather than speculative inventory.
Staged product development
Core, research, evaluation and phase-two layers stay visibly separate.